Anti-VEGF Treatment of Diabetic Macular Edema in Denmark: Incidence, Burden of Therapy, and Forecasting Analyses

Abstract

BACKGROUND: The aim of this study was to analyze demographically stratified incidence rates of patients with diabetic macular edema (DME) commenced in anti-VEGF therapy, to study temporal trends, to report the proportion of patients in active therapy over time, and to develop a model to forecast the future number of patients in active treatment.

METHODS: This was a retrospective registry-based study of all patients with DME who received at least one intravitreal anti-VEGF treatment from 1 January 2007 to 30 June 2022. Population data were extracted from Statistics Denmark.

RESULTS: This study included 2220 patients with DME who were commenced in anti-VEGF therapy. Demographic analyses revealed higher incidence rates among males than females and among those aged 60-80 years. The number of patients in active treatment followed an exponential decay curve; hence, this was used to mathematically model the number of patients in active therapy. The number of patients in active treatment is expected to stay relatively stable with a minimal increase until the year 2023.

CONCLUSIONS: This study provides insight into the practical aspects of the anti-VEGF treatment of DME that allow the planning of adequate health services.

OriginalsprogEngelsk
Artikelnummer546
TidsskriftJournal of Personalized Medicine
Vol/bind13
Udgave nummer3
Sider (fra-til)1-11
Antal sider11
ISSN2075-4426
DOI
StatusUdgivet - 18 mar. 2023

Fingeraftryk

Dyk ned i forskningsemnerne om 'Anti-VEGF Treatment of Diabetic Macular Edema in Denmark: Incidence, Burden of Therapy, and Forecasting Analyses'. Sammen danner de et unikt fingeraftryk.

Citationsformater